A Study to Test the Efficacy and Safety of SAR442970 in Adults With Hidradenitis Suppurativa

Inclusion Criteria:

• Participants with a history of signs and symptoms consistent with hidradenitissuppurativa (HS) for at least 1 year prior to Baseline.

• Participants must have HS lesions present in at least 2 distinct anatomic areas (eg,left and right axilla; or left axilla and left inguinocrural fold), one of whichmust be Hurley Stage II or Hurley Stage III.

• Participant must have had an inadequate response to a trial of an oral antibioticfor treatment of HS, exhibited recurrence after discontinuation of antibiotics,demonstrated intolerance to antibiotics, or has a contraindication to oralantibiotics for treatment of their HS as assessed by the Investigator throughparticipant interview and review of medical history.

• Participants must be either biologic and small molecule immunosuppressive-naïve orTNF-experienced.

• Participant must have a total abscess and inflammatory nodule (AN) count of ≥3 atthe Baseline visit.

• Participant must have a draining tunnel count of ≤20 at the Baseline visit.

• Participant must have a C-reactive protein (CRP) >3 mg/L at the screening visit.

• Participant who is a candidate for systemic treatment per Investigator's judgment.

Exclusion Criteria:

• Any other active skin disease or condition (eg, bacterial, fungal or viralinfection) that may interfere with assessment of HS

• History of recurrent or recent serious infection

• Known history of or suspected significant current immunosuppression

• History of solid organ transplant

• History of splenectomy

• History of moderate to severe congestive heart failure

• Receipt of a live vaccine 12 week prior to Baseline visit or receipt of a killedvaccine 2 weeks prior to Baseline visit

• History of demyelinating disease (including myelitis) or neurologic symptomssuggestive of demyelinating disease

• Participants with a history of malignancy or lymphoproliferative disease other thanadequately treated or nonmetastatic squamous cell carcinoma, or nonmetastatic basalcell carcinoma of the skin that was excised and completely cured

• Participants with a diagnosis of inflammatory conditions other than HS

• Presence of active suicidal ideation, or positive suicide behavior or participanthas a lifetime history of suicide attempt, or participant has had suicidal ideationin the past 6 months as indicated by a positive response using the screening orBaseline version of the Columbia-Suicide Severity Rating Scale (C-SSRS) or asassessed by the Investigator through participant interview and review of medicalhistory

• A history of an adverse event (AE) to anti-TNF therapy (examples include, but arenot limited, to serum sickness or anaphylaxis) for an HS or non-HS indication thatwould contraindicate readministration of an anti-TNF class therapy

• Sensitivity to any of the study interventions, or components thereof, or drug orother allergy that, in the opinion of the Investigator, contraindicatesparticipation in the study

• Female participants who are breastfeeding or considering becoming pregnant duringthe study

• History (within last 2 years prior to Baseline) of prescription drug or substanceabuse, including alcohol, considered significant by the Investigator

• Laboratory exclusion criteria apply

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.